Invega Sustenna FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved July 31, 2009)
Brand name: Invega Sustenna
Generic name: paliperidone palmitate
Dosage form: Extended-Release Injectable Suspension
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Schizophrenia, Schizoaffective Disorder
Invega Sustenna (1-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia and schizoaffective disorder.
Development Timeline for Invega Sustenna
|Nov 13, 2014||Approval FDA Approves sNDA for Invega Sustenna (paliperidone palmitate) for Schizoaffective Disorder|
|Aug 3, 2009||Approval FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.